SCHEMBL384128

SCHEMBL384128

O=C(Oc1ncc[nH]1)Oc1ncc[nH]1

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
TBXAS1 P24557 2/20 0.34
CSNK1A1 P48729 1/20 0.33
TYRO3 Q06418 1/20 0.33
DYRK1B Q9Y463 1/20 0.33
KMT2A Q03164 1/20 0.33
FDPS P14324 3/20 0.32
SMPD3 Q9NY59 1/20 0.31
MTOR P42345 1/20 0.30
ADK P55263 1/20 0.30
NISCH Q9Y2I1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11334976 0.88 ALDH1A1 (0.44) ALDH1A1KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL7766524 0.86 ALDH1A1 (0.41) ALDH1A1KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL3995849 0.86 TBXAS1 (0.37) ALDH1A1KDM4ESMN1; SMN2NPC1RAB9A
Hydrochloric Acid SCHEMBL2493637 0.84 ALDH1A1 (0.40) ALDH1A1KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL9063985 0.84 ALDH1A1 (0.40) ALDH1A1KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL667770 0.84
SCHEMBL2565429 0.83 ALDH1A1 (0.40) ALDH1A1KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL11335584 0.83 ALDH1A1 (0.34) ALDH1A1KDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL145933 0.83
SCHEMBL22404 0.83

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 391 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3687652-B1 HIGH PURITY CHROMATOGRAPHIC MATERIALS COMPRISING AN IONIZABLE MODIFIER FOR RETENTION OF ACIDIC ANALYTES WATERS TECHNOLOGIES CORP (US) 2025-07-09 EP claimed
US-12252557-B2 Charged surface reversed phase chromatographic materials method for analysis of glycans modified with amphipathic, strongly basic moieties WATERS TECHNOLOGIES CORPORATION (US) 2025-03-18 US claimed
CN-110249052-B Synthetic guide molecules, compositions, and methods related thereto 爱迪塔斯医药公司 2024-04-12 CN claimed
CN-117500817-A Peptides comprising phosphorylcholine conjugates and methods of synthesizing the same 塔西亚制药公司 2024-02-02 CN claimed
CN-117054585-A Charged surface reversed phase chromatography material method for analysis of glycans modified with amphiphilic strong basic moieties 沃特世科技公司 2023-11-14 CN claimed
CN-109154604-B Charged surface reversed phase chromatography material method for analysis of glycans modified with amphiphilic strong basic moieties 沃特世科技公司 2023-07-21 CN claimed
EP-4129466-A1 HIGH PURITY CHROMATROGRAPHIC MATERIALS COMPRISING AN IONIZABLE MODIFIER Waters Technologies Corporation (US) 2023-02-08 EP claimed
CN-112321399-B Preparation method of chemical intermediate 漯河豫博生物化工有限公司 2022-10-18 CN claimed
CN-114524812-A Crystal form preparation and synthesis method of 1, 4-dihydro-1, 6-naphthyridine compound 湖南凯铂生物药业有限公司 2022-05-24 CN claimed
CN-112299968-B Preparation method of chemical raw material 广州彼西络科技有限公司 2022-05-06 CN claimed
US-20050038256-A1 Synthetic process for trans-aminocyclohexyl ether compounds CARDIOME PHARMA CORP. (CA) 2005-02-17 US claimed
US-20030180804-A1 Solid phase synthesis of chemical libraries CORVAS INTERNATIONAL, INC 2003-09-25 US claimed
WO-2003037326-A1 SOLID PHASE SYNTHESIS OF CHEMICAL LIBRARIES CORVAS INTERNATIONAL, INC. (US) 2003-05-08 WO claimed
EP-1209205-A1 Improved process and method for the preparation of asymetric monofunctionalised indocyanine labelling reagents and obtained compounds Innosense S.r.l. (IT) 2002-05-29 EP claimed
EP-0923566-A4 HIGH MOLECULAR WEIGHT POLYMER-BASED PRODRUGS ENZON INC (US) 2001-10-10 EP claimed
JP-2000517304-A 2000-12-26 JP claimed
US-6011042-A POLYMERIC PRODRUGS ARE PREFERABLY ESTERS OF HYDROXYL-CONTAINING AROMATIC COMPOUNDS AND ARE FORMED BY REACTING A DESIRED AROMATIC, HYDROXYL-CONTAINING COMPOUND WITH A SUBSTANTIALLY NON-ANTIGENIC POLYMER ENZON, INC. (US) 2000-01-04 US claimed
US-5965566-A A WATER SOLUBLE BIOLOGICAL ACTIVE DRUG CONJUGATED WITH POLYOXYETHYLENE GLYCOL THROUGH A HYDROLYZABLE ESTER LINKAGING SPACER; CONTROLLED RELEASE PROPERTIES ENZON, INC. (US) 1999-10-12 US claimed
EP-0923566-A1 HIGH MOLECULAR WEIGHT POLYMER-BASED PRODRUGS ENZON, INC. (US) 1999-06-23 EP claimed
WO-1998007713-A1 HIGH MOLECULAR WEIGHT POLYMER-BASED PRODRUGS ENZON, INC. (US) 1998-02-26 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030180804-A1 Solid phase synthesis of chemical libraries PEPD, DNPEP, PRSS1 ALDH1A1 3434/4885KDM4E 2571/4885SMN1; SMN2 3967/4885
US-20050038256-A1 Synthetic process for trans-aminocyclohexyl ether compounds AKR1C3, CBR1, CBR3 ALDH1A1 1484/4885KDM4E 3727/4885SMN1; SMN2 4168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.